These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2288831)

  • 41. Digital blood flow response to body warming, cooling, and rewarming in patients with Raynaud's phenomenon.
    Lau CS; Khan F; Brown R; McCallum P; Belch JJ
    Angiology; 1995 Jan; 46(1):1-10. PubMed ID: 7818151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 45. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
    Freedman RR; Girgis R; Mayes MD
    J Rheumatol; 2001 Jan; 28(1):119-21. PubMed ID: 11196511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
    Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
    Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. L-arginine therapy in Raynaud's phenomenon?
    Agostoni A; Marasini B; Biondi ML; Bassani C; Cazzaniga A; Bottasso B; Cugno M
    Int J Clin Lab Res; 1991; 21(2):202-3. PubMed ID: 1815764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hemodynamic response of the digital artery to heat and cold in normal subjects, in systemic scleroderma and in Raynaud's disease].
    Vayssairat M; Mathieu JF; Housset E
    J Mal Vasc; 1984; 9(1):7-10. PubMed ID: 6707534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
    Kristensen JK; Engelhart M; Nielsen T
    Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Plethysmographic measurement of digital blood flow in Raynaud's phenomenon caused by vibrating tools].
    Casula D; Nissardi GP; Sanna-Randaccio F; Torrazza PL
    Minerva Cardioangiol; 1969 Jun; 17(6):386-98. PubMed ID: 5385423
    [No Abstract]   [Full Text] [Related]  

  • 58. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laser Doppler velocimetry of fingertips during heat provocation in normals and in patients with Raynaud's phenomenon.
    Wollersheim H; Reyenga J; Thien T
    Scand J Clin Lab Invest; 1988 Feb; 48(1):91-5. PubMed ID: 2975399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Raynaud's syndrome: study of fingertip blood flow by plethysmography with venous occlusion (author's transl)].
    Cristol R; Graisely B; Cloarec M; Debray J
    Nouv Presse Med; 1979 Jan; 8(2):105-8. PubMed ID: 554069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.